'Options Action' Traders Weigh In On Pfizer

On CNBC's "Options Action," traders answered a question from a viewer about Pfizer Inc. PFE. He was interested to know their opinion about a purchase of the January $40 call option.

Carter Worth thinks that is a really good bet. There is enough time and he would be comfortably long. The stock had a big day on Friday on expanding volume, and it was news-related.

Mike Khouw also likes the trade and the timing. The stock has low volatility and low implied volatility, so the options themselves tend not to cost that much, said Khouw.